Skip to content
buyWeak

Timothy A Springer bought $366k of RNAC

director, owner at Cartesian Therapeutics, Inc.. 20,967 shares at an average of $17.47, traded Jan 13, 2025, filed Jan 15, 2025.

Conviction score
30
Value
$366k
20,967 shares
Holdings after
8,531,462
+0% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    Director
    +15
  • Trade size
    $366k at market
    +15
  • Relative to holdings
    Under 1% of holdings (0.2%)
    -5
  • Price context
    No price history yet
    0
  • Cluster
    No other insider buying within 14 days
    0
  • Repeat buying
    3 buys in 90 days
    +5
  • Track record
    Too few past buys to judge (0 with prices)
    0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

RNACOct 9, 2026 · close 7.05
Since filing Jan 15, 2025: -62.8%SPY +33.9% · excess -96.7%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001453687-25-000047, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jan 13, 2025POpen-market purchase
Common Stock
+7,962$16.86$134k8,518,457Jan 15, 2025
Jan 13, 2025POpen-market purchase
Common Stock
+8,983$17.78$160k8,527,440Jan 15, 2025
Jan 14, 2025POpen-market purchase
Common Stock
+4,022$18.00$72k8,531,462Jan 15, 2025

Related signals

Other insiders at Cartesian Therapeutics, Inc. and this insider’s other filings.

ScoreSideCompanyInsiderValueSharesFiled
45ModeratebuyRNAC
Cartesian Therapeutics, Inc.
Timothy A Springer
director, owner
$1.4M89,863
54Moderatesell 6RNAC
Cartesian Therapeutics, Inc.
Carsten Brunn
President and CEO
$290k17,271
48Moderatesell 6RNAC
Cartesian Therapeutics, Inc.
Blaine Davis
Chief Financial Officer
$134k7,989
40Moderatesell 6RNAC
Cartesian Therapeutics, Inc.
Emily English
Chief Operations Officer
$30k1,797
36Weaksell 6RNAC
Cartesian Therapeutics, Inc.
Christopher M Jewell
Chief Scientific Officer
$43k2,550
35Weaksell 6RNAC
Cartesian Therapeutics, Inc.
Milos Miljkovic
Chief Medical Officer
$32k1,880
39Weaksell 6RNAC
Cartesian Therapeutics, Inc.
Metin Kurtoglu
Chief Technology Officer
$82k4,875
40ModeratebuyRNAC
Cartesian Therapeutics, Inc.
Timothy A Springer
director, owner
$965k52,189
20WeaksellRNAC
Cartesian Therapeutics, Inc.
Metin Kurtoglu
Chief Technology Officer
$345k13,664
55Moderatesell 3RNAC
Cartesian Therapeutics, Inc.
Metin Kurtoglu
Chief Technology Officer
$649k38,689

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Timothy A Springer bought $366k of RNAC | InsiderTell